Canopy Growth (NYSE: CGC), which is considered a leading marijuana stock, is reconfiguring itself with a pair of deals announced on Monday.
The first is the company's closing of its acquisition of U.K.-based Beckley Canopy Therapeutics. That entity, which focuses on the research of cannabis-based pharmaceuticals, was a joint venture it formed in 2018 with a think tank called Beckley Research & Innovation.
Image source: Getty Images.
Source Fool.com